Press releases

Press release
Medivir strengthens its business development possibilities through a renegotiated agreement with TetraLogic regarding birinapant

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB (“Medivir” or “the Company”) has renegotiated its agreement with...

Read more
Press release
Notice of extraordinary general meeting of Medivir AB (publ)

The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...

Read more
Press release
MEDIVIR RESOLVES ON A RIGHTS ISSUE OF APPROXIMATELY SEK 170 MILLION AND AN OVER-ALLOTMENT OPTION WITH STRONG SUPPORT FROM EXISTING AND NEW SPECIALIST INVESTORS

The Board of Directors of Medivir AB (publ) (”Medivir” or “the Company”) has today resolved to carry out a rights issue...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2020

July – September Significant events during the quarter In July, a research collaboration was initiated with the Drug Discovery and Development...

Read more
Press release
Medivir appoints Dr. Tom Morris as interim Chief Medical Officer

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective...

Read more
Press release
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2020

April – June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European...

Read more
Press release
Yilmaz Mahshid takes office as CEO of Medivir on 14 September

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September...

Read more
Press release
Medivir and SciLifeLab enter collaboration on potential SARS CoV-2 inhibitors

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery...

Read more
Press release
The European Commission has granted Orphan Medicinal Product Designation in the EU for MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the...

Read more
Press release
Medivir appoints Yilmaz Mahshid as new CEO

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new...

Read more
Press release
FDA grants MIV-818 Orphan Drug Designation for the treatment of hepatocellular carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 5 May 2020

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...

Read more